Rigontec: Merck & Co. to Buy German Immuno-Oncology Firm in Nearly $560-Million Dea

On Sep. 6, 2017, Merck & Co. announced that it will acquire Rigontec, a German immuno-oncology company specializing in retinoic acid-inducible gene I (RIG-I)-targeting therapeutics, in a deal worth up to EUR 464 million (US$557 million). Under the agreement, Merck, through a subsidiary